Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
Summarize this article with:
SA Transcripts157.38K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM EST Company Participants Thomas Larsen - Head of Investor RelationsHouman Ashrafian - Executive VP & Head of Research DevelopmentJean-Francois Toussaint - Global Head of Research & Development Vaccines - Sanofi Pasteur Conference Call Participants Peter Verdult - BNP Paribas, Research DivisionLuisa Hector - Joh. Berenberg, Gossler & Co. KG, Research DivisionRichard Vosser - JPMorgan Chase & Co, Research DivisionSachin Jain - BofA Securities, Research DivisionSimon Baker - Rothschild & Co Redburn, Research DivisionJames Quigley - Goldman Sachs Group, Inc., Research DivisionSarita Kapila - Morgan Stanley, Research DivisionGraham Glyn Parry - Citigroup Inc., Research DivisionChristopher LoBianco - TD Cowen, Research DivisionEmmanuel Papadakis - Deutsche Bank AG, Research Division Presentation Thomas LarsenHead of Investor Relations Good afternoon and good morning, depending on where you are, and welcome to the Sanofi's first year-end late-stage pipeline review. I'm Thomas Kudsk Larsen from the Investor Relations team and I'm pleased to see so many people on the call today. Before we get started, I want to thank Alizé in the IR team for leading the work on today's call. I also want to remind everyone that our focus is on the clinical and regulatory aspects of the mid- and late-stage pipeline. So we will aim at keeping any commercial or finance questions for another day. We want science and patience to take center stage. During the call, we'll highlight the most important events in 2025 across our pipeline in immunology, rare diseases, hemato-oncology, neurology and vaccines and provide the key news flow items for the first half and the second half of next year and 2027. Because a couple of 2025 news items deflated expectations, we believe that next year's news flow comes with lower anticipation in general. The presentation will